Physician profile
Daniel S Ring
NPI 1790778249
$18,770.69
in general payments reported to CMS, 2019-2025
47 companies · $3,611 in 2025
The $3,611 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,903 · 2020: $1,356 · 2021: $1,511 · 2022: $2,449 · 2023: $3,442 · 2024: $3,500 · 2025: $3,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,221.45 |
| Education | $331.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,892.14 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,573.88 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,293.97 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $980.57 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $943.97 | 2019-2025 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $894.42 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $845.47 | 2019-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $836.25 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $772.02 | 2022-2024 | Vtama |
| Incyte Corporation | $763.70 | 2021-2025 | Opzelura |
| Prugen, INC. Pharmaceuticals | $738.31 | 2019-2020 | |
| Pfizer INC. | $721.14 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $680.29 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $548.67 | 2019-2025 | Epsolay, Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.37 | 2022-2025 | Spevigo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $367.65 | 2019-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $342.52 | 2020-2025 | |
| Celgene Corporation | $321.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $313.96 | 2019-2025 | |
| Organogenesis INC. | $248.56 | 2024-2025 | Puraply Wound Matrix |
| Kerecis Limited | $245.71 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Genzyme Corporation | $243.32 | 2019-2024 | |
| Epi Health, LLC | $237.72 | 2020-2022 | |
| Botanix Sb INC | $234.86 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $232.37 | 2019-2025 | |
| Strata Skin Sciences, INC. | $157.94 | 2019-2025 | Xtrac |
| Regeneron Pharmaceuticals, INC. | $134.95 | 2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $124.24 | 2025 | Tremfya |
| Almirall LLC | $122.36 | 2019-2025 | Klisyri, Seysara |
| Biofrontera INC. | $104.31 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $59.81 | 2025 | Vtama |
| Mission Pharmacal Company | $54.25 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.31 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Merz North America, INC. | $38.48 | 2019 | |
| Aclaris Therapeutics, INC. | $32.14 | 2019 | |
| Genentech USA, INC. | $31.71 | 2019 | |
| Allergan, INC. | $27.10 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.92 | 2022 | |
| Dermira, INC. | $18.83 | 2020 | |
| Dusa Pharmaceuticals, INC. | $17.91 | 2019 | |
| Vyne Pharmaceuticals INC. | $17.42 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $17.27 | 2019 | |
| Tactile Systems Technology INC | $16.89 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $16.55 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.14 | 2019 | |
| Misonix INC | $14.69 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.